Peptides for Weightloss: Which Ones Are Studied and How They Compare (2026)
Search “peptides for weight loss” and the results blur two different worlds together: prescription GLP-1 medicines with landmark human trials, and research-use-only compounds with almost no human data at all. Separating those two groups is the job of this page.
The Compound Universe take: Peptides for weight loss means semaglutide, tirzepatide, and retatrutide to anyone reading the trial data, three agonists behind 68-to-72-week randomized trials producing 15 to 24 percent average body-weight loss against roughly 2 percent for placebo. Retatrutide’s 24.2 percent phase 2 result is the biggest number in the category, but a phase 2 average is not a phase 3 approval, and everything else marketed under this term (tesamorelin, AOD-9604, MOTS-c) is indication-limited or evidence-thin by comparison.
See the two FDA-approved options ranked head-to-head.
For a ranked side-by-side of these compounds, see the ranked comparison of peptides for weight loss; this page covers the category and the evidence quality behind it.
What “peptides for weight loss” actually covers
A peptide is a short chain of amino acids, and several distinct chemical families get marketed under the weight-loss umbrella, some approved prescription drugs, others growth-hormone fragments sold as research chemicals. Grouping them into one bucket, as most retail sites do, hides that they share neither a mechanism nor an evidence base.
The two clusters worth knowing:
- Incretin-based agonists (semaglutide, tirzepatide, retatrutide): synthetic peptides mimicking gut hormones, GLP-1, GIP, and glucagon, slowing gastric emptying and appetite [1][2][3].
- Growth-hormone-axis peptides (tesamorelin, AOD-9604): act on the growth-hormone pathway or a fat-mobilizing fragment of it, with a thinner, mixed human record [4][5].
| Peptide | What it is | Evidence tier |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist (FDA-approved for weight management) | Human (large RCTs) |
| Tirzepatide | Dual GLP-1/GIP receptor agonist (FDA-approved for weight management) | Human (large RCTs) |
| Retatrutide | Triple GLP-1/GIP/glucagon receptor agonist, investigational | Human phase 2 |
| Tesamorelin | Growth-hormone-releasing hormone (GHRH) analog | Human RCT (HIV lipodystrophy indication) |
| AOD-9604 | C-terminal fragment of growth hormone (176-191) | Human trial, did not reach significance |
| MOTS-c | Mitochondrial-derived peptide studied for metabolic effects | Animal + early human |
The peptides most studied for weight loss
Semaglutide: the GLP-1 comparison point
Semaglutide is a modified GLP-1 peptide that activates the GLP-1 receptor, slowing digestion and reducing hunger signals in the brain. In the STEP 1 trial, 1,961 adults with obesity or overweight took once-weekly semaglutide or placebo for 68 weeks alongside lifestyle counseling. The semaglutide group lost a mean of 14.9 percent of body weight versus 2.4 percent with placebo, and 86.4 percent reached at least a 5 percent loss [1]. Human (RCT): this is one of the largest, best-controlled weight-loss trials ever run on a peptide drug.
Semaglutide is FDA-approved for chronic weight management, a prescription medicine, not a research-use-only product.
Tirzepatide: dual-hormone agonism
Tirzepatide activates both the GLP-1 and GIP receptors. Its SURMOUNT-1 trial enrolled 2,539 adults with obesity, randomized to 5 mg, 10 mg, 15 mg, or placebo weekly for 72 weeks. Average weight loss reached 16.0, 21.4, and 22.5 percent across doses, versus 2.4 percent for placebo [2]. Human (RCT): the dual-receptor mechanism appears to add magnitude on top of the GLP-1 effect alone.
Like semaglutide, tirzepatide is FDA-approved, not a research chemical.
Retatrutide: the investigational triple agonist
Retatrutide adds a third mechanism, glucagon receptor activity, to the GLP-1/GIP combination. In a 48-week phase 2 trial, the highest dose group lost a mean of 24.2 percent versus 2.1 percent for placebo [3]. Human phase 2: the largest reductions reported so far for this class, but retatrutide remains investigational.
Tesamorelin: growth-hormone-releasing hormone, narrow indication
Tesamorelin is a GHRH analog that stimulates the body’s own growth hormone release. A randomized trial in people with HIV-associated abdominal fat accumulation found tesamorelin reduced visceral fat and liver fat significantly more than placebo over 6 months [4]. Human (RCT): the effect is real, but the approval and the trial population are specific to HIV-associated lipodystrophy, not general weight loss.
AOD-9604 and MOTS-c: the thin-evidence end
AOD-9604 for fat loss
AOD-9604 isolates a fragment of growth hormone thought to drive fat breakdown without growth-hormone’s other effects. Its largest phase 2b obesity trial, roughly 536 subjects over 24 weeks, did not reach statistical significance against placebo, and the program was discontinued [5]. Human trial (negative): a rare case where the data argues against the marketed claim.
MOTS-c and mitochondrial weight regulation
MOTS-c is a mitochondrial-derived peptide studied for AMPK activation, the cell’s energy-sensing pathway, and for improving insulin sensitivity in animal models [6][7]. Animal + early human: MOTS-c activates AMPK signaling in these models, but a controlled human weight-loss trial does not yet exist.
Compound Universe take: A discontinued 536-subject trial is a more useful data point than most peptides on this page ever generate, precisely because it failed: AOD-9604 got a real phase 2b test against placebo and lost, a stronger evidence signal than MOTS-c’s total absence of human weight-loss trials. On a hub ranked by evidence quality, a well-powered negative result should sit above an untested compound, even though vendor marketing treats both as equally viable.
How proven these peptides really are
| Peptide | Primary mechanism | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonism; appetite and gastric-emptying effects | Human, large RCTs | FDA-approved (prescription) |
| Tirzepatide | Dual GLP-1/GIP receptor agonism | Human, large RCTs | FDA-approved (prescription) |
| Retatrutide | Triple GLP-1/GIP/glucagon receptor agonism | Human phase 2 | Investigational, not approved |
| Tesamorelin | GHRH-analog stimulation of endogenous growth hormone | Human RCT (narrow indication) | FDA-approved for HIV lipodystrophy only |
| AOD-9604 | Growth-hormone C-terminal fragment; proposed beta-3 receptor activity | Human trial, non-significant | Not FDA-approved |
| MOTS-c | Mitochondrial-derived peptide; AMPK activation | Animal + early human | Not FDA-approved |
Compound Universe take: Tesamorelin’s visceral-fat trial is genuine human RCT evidence, not a maybe, but it enrolled patients with HIV-related visceral fat accumulation, a population selected for a specific fat-distribution pattern most weight-loss searchers don’t share. Borrowing that result for general weight loss stretches a well-controlled trial past the question it was built to answer, a different failure mode than AOD-9604 or MOTS-c simply lacking the data in the first place.
Get the full retatrutide phase 2 trial breakdown before drawing conclusions.
The category name implies similar backing; the trial record says otherwise:
| Peptide | Evidence stage | Bottom line |
|---|---|---|
| Semaglutide, tirzepatide | Established | Large RCTs, dose-dependent, FDA-approved |
| Retatrutide | Emerging | Largest phase 2 effect size, not yet approved |
| Tesamorelin | Established (narrow indication) | Solid RCT, confined to HIV-related fat loss |
| AOD-9604 | Research-stage (negative) | Human trial failed to beat placebo |
| MOTS-c | Research-stage | No human weight-loss trial exists yet |
Read this before comparing options: Semaglutide and tirzepatide are FDA-approved prescription medicines requiring a clinician relationship, not research chemicals. Tesamorelin is FDA-approved only for a narrow HIV-related indication. AOD-9604 and MOTS-c are not FDA-approved, and raw-peptide versions are typically sold “for research use only.” This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use.
Key takeaways
- Semaglutide and tirzepatide have the strongest human evidence, with large randomized trials showing double-digit percentage weight loss over 68-72 weeks [1][2].
- Retatrutide, a triple GLP-1/GIP/glucagon agonist, produced the largest average reductions reported in phase 2, but it remains investigational [3].
- Tesamorelin reduces visceral fat in a randomized trial, though its approval is limited to HIV-associated abdominal fat accumulation, not general weight loss [4].
- AOD-9604’s largest obesity trial failed to reach statistical significance, which undercuts its common fat-loss marketing [5].
- MOTS-c’s weight-related evidence is animal and early-human only, tied to AMPK activation and insulin sensitivity, not a controlled weight-loss trial [6][7].
Frequently asked questions
What peptide has the most research behind it for weight loss?
Semaglutide and tirzepatide have the deepest trial record, trials of nearly 2,000 and over 2,500 participants showing sustained weight loss versus placebo [1][2].
Is retatrutide better than semaglutide or tirzepatide?
Retatrutide’s phase 2 results show larger average weight-loss percentages, but it has not completed the phase 3 trials or approval process that semaglutide and tirzepatide have, so a direct real-world comparison is not yet established [3].
Does tesamorelin help with general weight loss?
Tesamorelin’s controlled human trial data covers visceral and liver fat reduction in people with HIV-associated abdominal fat accumulation specifically, not general weight loss in the broader population [4].
Does AOD-9604 actually work for fat loss?
Its largest obesity trial, roughly 536 participants over 24 weeks, did not show a statistically significant effect versus placebo, and the program was discontinued [5].
Is MOTS-c a legitimate weight-loss peptide?
MOTS-c is a real research subject in metabolic biology, studied for AMPK activation and insulin sensitivity in animal models, but it lacks a controlled human trial [6][7].
Are peptides for weight loss legal?
Semaglutide and tirzepatide are FDA-approved prescription drugs, tesamorelin is FDA-approved for a narrow HIV-related use, and other peptides discussed here are not FDA-approved and are commonly sold as research chemicals; legal status differs by compound and changes over time.
Interest in peptides for weight loss spans incretin biology, where semaglutide and tirzepatide act on GLP-1 and GIP receptors and retatrutide extends that mechanism to glucagon, growth-hormone-axis science, where tesamorelin’s GHRH-analog activity and AOD-9604’s growth-hormone fragment sit at different evidence tiers, and mitochondrial metabolism, where MOTS-c’s AMPK-linked signaling ties back to broader energy and insulin-sensitivity research; Compound Universe tracks each compound against the primary literature so the summary reflects trial quality, not marketing volume.
Confirm what’s actually legal before you weigh any option.
Peptides for weight loss split cleanly into two tiers: prescription GLP-1/dual/triple agonists with large controlled trials, and growth-hormone-axis or mitochondrial compounds with a thinner, sometimes negative, record. See semaglutide vs tirzepatide, Compound Universe’s guide to peptide legality, or the tesamorelin research summary for the full visceral-fat data.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
- Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID 25038357.
- AOD-9604 phase 2b obesity trial (Metabolic Pharmaceuticals Ltd., approximately 536 subjects, 24 weeks): did not reach statistical significance versus placebo; program discontinued 2007. (VERIFY exact trial registry citation before publish; no indexed PubMed record located this session).
- Lee C, et al. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. PMID 27216708 / PMC5116416.
- The mitochondrial-derived peptide MOTS-c enhances insulin sensitivity. PMC6640593.